share:    TwitThis      StumbleUpon      Ping.fm      del.icio.us      Facebook      Digg      Mixx      MySpace      Slashdot      Reddit      Technorati      Ma.gnolia      Propeller      Google      Live      TailRank      Tumblr      Tell a friend!


Recommend CitePlanet! to your friends
4 Star hotels at 2 star prices with low Hotwire Hot-Rates!


Source Origin:  Click here Email this citation
   

Management of Chronic Myelogenous Leukemia

Michael Steinberg          
2007 July 13
--------------------------------------------------------
Dasatinib is approved by the FDA for use in the treatment of patients with chronic, accelerated, or myeloid or lymphoid blast phases of Chronic myelogenous leukemia (CML) or with Ph+ ALL that has developed resistance or intolerance to previous therapy.
--------------------------------------------------------
--------------------------------------------------------
Electronic Source
Subject: Health Publisher:  U.S. Pharmacist
Volume:  32 Number:  7
Page/Paragraph:  NULL Number of Volumes Cited:  1
CiteNumber:  2532 Contributor:  jwalker
View URL: Click here
--------------------------------------------------------
Browse by:
Current Title      Current Publisher     Current Subject     Current Contributor
Edit/Delete this Citation
Citation Formatter
APA Style

Steinberg, M. (2007). Management of Chronic Myelogenous Leukemia. U.S. Pharmacist, 32(7). Retrieved September 8, 2010, from http://www.uspharmacist.com/index.asp?show=article&page=8_2077.htm



MLA Style

Steinberg, Michael. ''Management of Chronic Myelogenous Leukemia.'' U.S. Pharmacist 32.7 (2007). 8 September 2010 <http://www.uspharmacist.com/index.asp?show=article&page=8_2077.htm>.



Chicago Manual of Style

Steinberg, Michael. ''Management of Chronic Myelogenous Leukemia.'' U.S. Pharmacist 32, no. 7 (2007). http://www.uspharmacist.com/index.asp?show=article&page=8_2077.htm (accessed September 8 2010).